Journey Medical (DERM) said Monday the US Food and Drug Administration approved Emrosi for the treatment of inflammatory lesions of rosacea, an inflammatory skin condition, in adults.
The company said it is completing the manufacturing of Emrosi for the US market, with initial supply expected to be available late in Q1 or early in Q2 2025.
Journey Medical said it developed Emrosi in collaboration with Dr. Reddy's Laboratories (RDY).
Price: 5.33, Change: -0.84, Percent Change: -13.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.